# Larimar Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/larimar-therapeutics

- Industry: Pharmaceuticals
- Headquarters: Bala Cynwyd, US
- Website: www.larimartx.com
- Total disclosed funding: $126M
- Latest round: Series E (Dec 4, 2013)
- Investors on record: 7

## About

Based in Pennsylvania, US, and founded in 2005 by founders Maria Rupnick, Larimar Therapeutics, Inc., formerly known as ZafGen Inc. (Nasdaq: LRMR), develops therapeutics for the treatment of metabolic disorders and type 2 diabetes. In September 2022, Larimar Therapeutics, Inc. raised USD 70 million in a private placement, selling 22.25 million shares at USD 3.15 per share on the NASDAQ.

Larimar's portfolio includes a proprietary intracellular delivery platform. This technology is designed to transport proteins and other critical molecules directly into target cells, addressing deficiencies at the root of rare diseases. The platform's versatility allows Larimar to engineer tailored fusion proteins designed to address specific biochemical deficits associated with various rare conditions. Additionally, CTI-1601 is under Phase 1 clinical trial, aiming to restore frataxin levels and potentially alleviate symptoms, marking a significant stride in rare disease treatment.

## Funding rounds

- Series E, Dec 4, 2013, $45M — Alta Partners, Venrock, RA Capital Management, Brookside Capital
- Series D, Dec 4, 2012, $21M — Alta Partners, Atlas Venture, Third Rock Ventures
- Series C, Jul 7, 2011, $33M — Atlas Venture, Third Rock Ventures
- Series B, Feb 17, 2010, $8.1M — Atlas Venture, Third Rock Ventures, GreatPoint Ventures
- Series B, Nov 17, 2008, $14M — Atlas Venture, Third Rock Ventures
- Series A, Aug 22, 2006, $5M — Atlas Venture, GreatPoint Ventures

## Investors

- Atlas Venture (https://capitalatlas.ai/funds/atlas-venture) — Series A, Series B, Series C, Series D
- GreatPoint Ventures (https://capitalatlas.ai/funds/greatpoint-ventures) — Series A, Series B
- Third Rock Ventures (https://capitalatlas.ai/funds/third-rock-ventures) — Series B, Series C, Series D
- Alta Partners (https://capitalatlas.ai/funds/alta-partners) — Series D, Series E
- Venrock (https://capitalatlas.ai/funds/venrock) — Series E
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series E
- Brookside Capital — Series E